The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition ofN-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino) phenylamino]-4-acridinecarboxamide (CI-921) in the rabbit

The clinical pharmacokinetics of N-5-dim

The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial

✍ J. W. Paxton; J. R. Hardy; P. C. Evans; V. J. Harvey; B. C. Baguley 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 528 KB

The pharmacokinetics of CI-921 were studied after 65 infusions over a 20-fold dose range (13-270 mg/m2 per day) in 16 patients during a phase 1 trial. CI-921 was given by a 15 min infusion on three consecutive days. Plasma samples were collected after the first and third infusions, and urine, at 6 h